A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients (CWP-DIANA-301)

January 2, 2013 updated by: JW Pharmaceutical

A Multicenter, Randomized, Double Blind, Placebo Controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate Efficacy and Safety of CWP-0403 in Type 2 DM Patients

This trial is to evaluate the efficacy and safety of CWP-0403 at 100 mg or 200 mg twice daily compared with placebo in type 2 diabetic patients with inadequate glycemic control by diet therapy or combination of diet and exercise therapy.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

117

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Type 2 DM patients
  • Subjects who couldn't control the blood glucose despite of a dietary and exercise therapy more than 6 weeks at screening visit
  • FPG ≤ 270mg/dL at screening visit
  • Patients who consent to participate in this trial by written Informed Consent Form

Exclusion Criteria:

  • Type 1 DM or secondary diabetes
  • Subjects who are administrating insulin or need to insulin therapy
  • History of oral anti-hyperglycemic drugs within 6 weeks before screening visit
  • Body mass index < 20 kg/m2 or > 40.0kg/m2
  • Subjects who are assessed to be inappropriate for this trial by investigator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo of CWP-0403 100mg
Drug: Placebo of Anagliptin
Placebo of Anagliptin 100mg, tablet, BID
Experimental: CWP-0403 200mg
Drug: Anagliptin
Anagliptin 100mg, tablet, BID
Experimental: CWP-0403 100mg
Drug: Anagliptin
Anagliptin 100mg, tablet, BID

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The Change in HbA1c from baseline to week24
Time Frame: 0wk, 8wk, 16wk, 24wk
0wk, 8wk, 16wk, 24wk

Secondary Outcome Measures

Outcome Measure
Time Frame
The proportion of subjects achieving HbA1c<7% at week24
Time Frame: 0wk, 8wk, 16wk, 24wk
0wk, 8wk, 16wk, 24wk
The proportion of subjects achieving HbA1c<6.5% at week24
Time Frame: 0wk, 8wk, 16wk, 24wk
0wk, 8wk, 16wk, 24wk
The change from baseline to week 24: Fasting plasma glucose
Time Frame: 0wk, 24wk
0wk, 24wk
change from baseline to week 24 in HOMA-IR
Time Frame: 0wk, 24 wk
0wk, 24 wk
change from baseline to week 24 in Fasting serum insulin
Time Frame: 0 wk, 24 wk
0 wk, 24 wk
change from baseline to week 24 in Fasting serum pro-insulin
Time Frame: 0 wk, 24wk
0 wk, 24wk
change in from baseline to week 24 fasting serum c-peptide
Time Frame: 0wk, 24wk
0wk, 24wk
change from baseline to week 24 in HOMA-β
Time Frame: owjm 24wk
owjm 24wk

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

JW Pharmaceutical

Investigators

  • Principal Investigator: Sung Woo Park, M.D., PhD, Kangbuk Samsung Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2011

Primary Completion (Actual)

September 1, 2012

Study Completion (Actual)

November 1, 2012

Study Registration Dates

First Submitted

February 6, 2012

First Submitted That Met QC Criteria

February 8, 2012

First Posted (Estimate)

February 9, 2012

Study Record Updates

Last Update Posted (Estimate)

January 4, 2013

Last Update Submitted That Met QC Criteria

January 2, 2013

Last Verified

January 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CWP-DIANA-301

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes Mellitus

Clinical Trials on Placebo of Anagliptin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe